ABC Classification Is Less Useful for Older Koreans Born before 1960

Hyungyung Kwon, Sun-Young Lee, Jun Hyun Kim, Sang Pyo Lee, Jeong Hwan Kim, In-Kyung Sung, Hyung Seok Park, and Chan Sup Shim

Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea

Background/Aims: In the ABC classification system, group A consists of seronegative subjects without gastric corpus atrophy. This study aimed to determine the prevalence and characteristics of pseudo group A subjects. Methods: Group A subjects were identified among consecutive Korean adults who underwent a serum anti- Helicobacter pylori immunoglobulin G (IgG) test and pepsinogen (PG) assay on the day of endoscopy. Past infection was defined as the presence of either eradication history or endoscopic findings suggesting past infection (i.e., gastric xanthoma, metaplastic gastritis, or advanced atrophy > closed-type 1). Results: Among 2,620 group A subjects, 448 (17.1%) had eradication history, and 133 (5.1%) showed endoscopic findings suggesting past infection. Older age (odds ratio [OR], 1.148; 95% confidence interval [CI], 1.067 to 1.236) and earlier year of birth (OR, 1.086; 95% CI, 1.009 to 1.168) were independent risk factors for classification into pseudo group A, with cutoff points at 50.5 years and birth year of 1959.5, respectively. Positive H. pylori test findings were found in 22 subjects (3.1%) among the 715 subjects who underwent the urea breath test or Giemsa staining on the same day. Current infection was positively correlated with PG I and PG II levels (p<0.001) but not with age, anti- H. pylori IgG titer, or classification into pseudo group A. Conclusions: Among the group A subjects, 22.2% had past infection. The risk was higher in subjects older than 50 years, especially those born before 1960. Furthermore, current infection was found in 3.1% of the subjects and was correlated with increased gastric secretory ability.

Key Words: Age; Helicobacter pylori; Serology; Pepsinogen

INTRODUCTION

 Helicobacter pylori infection and gastric atrophy are well-known causes of gastric cancer. Despite improved eradication and sanitation, H. pylori infection is still common in regions where endoscopic gastric cancer screening has been widely performed without eradication. H. pylori infection is responsible for 56.5% of infection-related cancer in Korea, followed by hepatitis B virus (23.9%), human papillomavirus (11.3%), and hepatitis C virus (6.0%). Although H. pylori-seropositivity in urban residents and in younger population is declining in Korea, the prevalence is still high in rural residents and in older population.

Combined serum anti- H. pylori immunoglobulin G (IgG) and pepsinogen (PG) testing is cost-effective for gastric cancer screening in H. pylori-seroprevalent population. ABC classification identifies gastric cancer risk based on the presence of gastric corpus atrophy (PG I level of ≤70 ng/mL and PG I/II ratio of ≤3.0) and H. pylori-seropositivity. Group A consists of seronegative subjects without gastric corpus atrophy, group B consists of seropositive subjects without gastric corpus atrophy, group C consists of seropositive subjects with gastric corpus atrophy, and group D consists of seronegative subjects with gastric corpus atrophy. Gastric secretory ability is unimpaired in groups A and B, and gastric cancer risk is lowest in group A. Conversely, gastric secretory ability is impaired in groups C and D, and gastric cancer risk is highest in group D owing to previous H. pylori infection.

Asymptomatic group A subjects are often excluded from the candidates for annual endoscopic gastric cancer screening; however, recent studies show that gastric cancers are not uncommon in group A. This may reflect the misclassification of seroreversed subjects with false negative findings in ABC classification system. In a recent Japanese study, the risk of gastric cancer in seroreversed subjects after eradication was similar to that in seropositive subjects. Because there is still a risk of gastric cancer after successful eradication or spontaneous regression, it is important to distinguish pseudo group A...
seroreversed subjects among the group A seronegative subjects. In addition to the pseudo group A subjects with past infection, it is important to discriminate group A subjects with current \textit{H. pylori} infection. The aim of this study was to determine the prevalence of the condition and characteristics of pseudo group A among group A subjects.

**MATERIALS AND METHODS**

1. **Study subjects**

Korean subjects over 18 years of age who underwent serum anti-\textit{H. pylori} IgG test and PG assay on the day of upper gastrointestinal endoscopy between January 2010 and June 2016 were analyzed. The subjects were included in the study, if they satisfied the criteria for group A (\textit{H. pylori}-seronegative subjects without gastric corpus atrophy) as per ABC classification. Exclusion criteria were subjects with previous gastrectomy or renal failure. Those who did not answer the questionnaire on past eradication were also excluded. This observational cohort study was approved by the Institutional Review Board of Konkuk University Medical Center (KUH1010626). All subjects provided informed consent before the tests. The study was performed in prospective and retrospective manner by collecting test findings.

2. **Questionnaires and endoscopic examination**

The subjects were asked about their medical history including successful \textit{H. pylori} eradication, gastrectomy, renal failure, hypertension, diabetes mellitus, coronary heart disease, and cerebrovascular attack. Questionnaires on social history included cigarette smoking (never, past, or current) and alcohol drinking (almost none, social, or heavy). Based on the National Institute for Alcohol Abuse and Alcoholism guideline, heavy drinking was defined as ≥8 drinks/wk for women and ≥15 drinks/wk for men. Recent drug intake within last 3 months were asked before the endoscopic examination.

After 12 hours of fasting, endoscopy was performed with the aid of either EG-2990i (Pentax, Tokyo, Japan) or GIF-H260 (Olympus, Tokyo, Japan). Endoscopic findings suggesting past infection were determined by the presence of gastric xanthoma (yellowish plaque), metaplastic gastritis (irregular whitish elevations and/or depressed patchy erythema), or advanced atrophy as described. Advanced atrophy was defined as visible submucosal vessels extending up to the body (closed-type 1 in Kimura-Takemoto classification) in this study, because the gastric cancer risk is increased from closed-type 2. Endoscopic images were reviewed by two gastroenterologists (H.K. and S.Y.L.).

3. **Diagnosis for \textit{H. pylori}-seronegativity**

Serum anti-\textit{H. pylori} IgG titer was measured by the Vidas \textit{H. pylori} IgG assay (BioMérieux, Marcy-l’Etoile, France) till 2012, and by the Chorus \textit{H. pylori} IgG (DIESSE Diagnostica Senese, Siena, Italy) thereafter. For the Vidas \textit{H. pylori} IgG assay, seronegativity was defined as test value (TV) of < 0.75 arbitrary units (AU/mL). Seropositivity was defined as TV of ≥1.00 AU/mL. For the Chorus \textit{H. pylori} IgG assay, seronegativity was defined as TV of <8.0 AU/mL, and seropositivity was defined as ≥12.0 AU/mL. Sensitivity and specificity of the Vidas assay were 89.7% and 85.5%, and those of the Chorus assay were 100% and 75.4% in Korean subjects, respectively.

Group A subjects were further classified into four subgroups according to their anti-\textit{H. pylori} IgG titer. For the Vidas \textit{H. pylori} IgG assay, the lowest first-quartile, second-quartile, third-quartile, and highest fourth-quartile were defined as the anti-\textit{H. pylori} IgG titer of (1) ≤0.2 AU/mL, (2) >0.2 and ≤0.4 AU/mL, (3) >0.4 and ≤0.6 AU/mL, and (4) >0.6 AU/mL. For the Chorus \textit{H. pylori} IgG assay, the quartiles were defined as the serology titer of (1) ≤5.0 AU/mL, (2) >5.0 and ≤6.0 AU/mL, (3) >6.0 and ≤7.0 AU/mL, and (4) >7.0 AU/mL, respectively.

4. **Serum pepsinogen assay and ABC classification**

Serum PG levels were analyzed using the latex enhanced turbidimetric immunoassay (Hbi Co., Anyang, Korea). Gastric corpus atrophy was defined as a combination of PG I level of ≤70 ng/mL and PG I/II ratio of ≤3.0. According to the ABC classification system, \textit{H. pylori} (+)/gastric corpus atrophy (−) subjects were classified into group A. Subjects showing \textit{H. pylori} (+)/gastric corpus atrophy (−) \textit{H. pylori} (+)/gastric corpus atrophy (+), and \textit{H. pylori} (−)/gastric corpus atrophy (+) were classified into groups B, C, and D, respectively.

5. **Definition of pseudo group A**

Pseudo group A owing to past infection was defined as seroreversed subjects after \textit{H. pylori} infection, who showed normal findings on anti-\textit{H. pylori} IgG and PG testings. If there was a history of successful \textit{H. pylori} eradication, subjects were classified into the pseudo group. Subjects with endoscopic findings suggesting past infection (gastric xanthoma, metaplastic gastritis, or advanced atrophy) were also classified into the pseudo group A. Unintended eradication or spontaneous regression was considered as a cause of seroreversion in the latter pseudo group A. Subjects without definite evidence of past infection were classified into true group A.

Current \textit{H. pylori} infection was defined as positive test findings either in the urea breath test (UBT) or on Giemsa staining on the day of endoscopy. UBT was done using Heliview mass spectrometry (MediChem, Seoul, Korea) as described in our previous study. \textit{H. pylori} infection was defined as different 13CO2 concentration between the baseline and 30 minutes samples of >2.4. For Giemsa staining, gastric biopsied specimens were fixed in 95% ethanol. Thereafter, the samples were embedded in paraffin blocks, and were sectioned for hematoxylin & eosin and Giemsa stainings as described.
6. Statistical analysis

Data were analyzed using PASW statistics version 17.0 (SPSS Inc., Chicago, IL, USA). A p-value of <0.05 was considered statistically significant. The κ-value was calculated to evaluate interobserver variability in the endoscopic findings. Differences between the two groups (i.e., true A and pseudo A) were analyzed using the t-test and chi-square test for continuous and categorical variables, respectively. Differences between three or four groups were analyzed by using the post-hoc analysis for continuous variables, and chi-square test with Bonferroni correction for categorical variables. Continuous variables were presented as mean±standard deviation, and were presented as proportion (%). Logistic regression analysis was done to verify independent risk factors for being pseudo group A (being misclassified into group A despite past infection). The values were presented as odds ratio and 95% confidence intervals. Receiver operating characteristic (ROC) curve analysis was done for significant continuous variables to determine cutoff values for being pseudo group A. Area under the curve and standard error were provided with sensitivity and specificity for each cutoff value.

RESULTS

1. Proportion of group A subjects and incidence of gastric neoplasm

Among 7,178 Korean adults who underwent serum PG assay and the anti-\textit{H. pylori} IgG test on the same day of endoscopy, 274 were excluded owing to equivocal anti-\textit{H. pylori} IgG test findings (Fig. 1). The subjects were classified into group A (n=2,620), group B (n=3,316), group C (n=898), or group D (n=70). The incidence of gastric adenoma and adenocarcinoma was 0.11% in group A, 0.33% in group B, 1.56% in group C, and 4.29% in group D (Supplementary Table 1). Among the group A subjects with gastric neoplasm, two were classified into pseudo group A. One subject showed advanced atrophy up to the lower body, and the other showed metaplastic gastritis on the antrum and body.

2. Proportion of pseudo group A subjects with past \textit{H. pylori} infection

Among the 2,620 group A subjects, 448 (17.1%) were classified into the pseudo group owing to previous \textit{H. pylori} eradication (Fig. 1). Additionally, 133 (5.1%) were also classified into the pseudo group owing to endoscopic findings suggesting past infection. Two gastroenterologists agreed that 139 subjects had endoscopic findings suggesting past \textit{H. pylori} infection (either gastric xanthoma, metaplastic gastritis, or advanced atrophy); a total of 2,434 subjects had no such findings. Discrepancy between the two gastroenterologists was found in 47 subjects (1.8%). The κ-value was 0.846 (p<0.001).

3. True group A versus pseudo group A with past infection

The true group A subjects were younger (p<0.001) and had a lower predominance of male sex (p=0.001) than the pseudo group A subjects (Table 1). The true group A subjects were born more recently (mean year of birth: 1962.7±11.5) than the pseudo group A subjects (1957.0±9.8). Moreover, the pseudo group A subjects showed higher prevalence of hypertension (p=0.002), diabetes mellitus (p=0.017), aspirin use (p=0.037), and cigarette smoking (p<0.001) than the true group A subjects. The true

![Flow diagram of study showing subject recruitment and selection criteria. Among the 7,178 Korean subjects, 2,620 Helicobacter pylori-seronegative subjects without gastric corpus atrophy were included in this study. Subjects with eradication history and those with abnormal endoscopic findings suggesting past infection were classified into pseudo group A. Endoscopic findings suggesting past infection were determined by the presence of gastric xanthoma, metaplastic gastritis, or advanced atrophy extending up to the body, because the gastric cancer risk is increased from closed-type 2.](image-url)
Table 1. Baseline Characteristics of the 2,620 Group A Subjects

| Variable                          | True A (n=2,039) | Pseudo A with past infection (n=581) | p-value | Pseudo A with eradication history (n=448) | p-value | Pseudo A with endoscopic findings suggesting past infection (n=133) | p-value |
|-----------------------------------|-----------------|--------------------------------------|---------|------------------------------------------|---------|------------------------------------------------------------------|---------|
| Age, yr                           | 49.5±11.3       | 55.7±9.7                             | <0.001  | 55.2±9.7                                 | 0.016   | 57.5±9.7                                                         | 0.006   |
| Year of birth                     | 1962.7±11.5     | 1957.0±9.8                           | <0.001  | 1957.6±9.8                               | 0.006   | 1954.9±9.6                                                      | 0.007   |
| Male sex                          | 1,061 (52.0)    | 349 (60.1)                           | 0.001   | 258 (57.6)                               | 0.025   | 91 (68.4)                                                       | 0.025   |
| Hypertension                      | 365 (17.9)      | 128 (22.0)                           | 0.027   | 102 (22.8)                               | 0.006   | 26 (19.5)                                                       | 0.007   |
| Diabetes mellitus                 | 129 (6.3)       | 50 (8.6)                             | 0.017   | 37 (8.3)                                 | 0.770   | 13 (9.8)                                                        | 0.770   |
| Coronary heart disease            | 67 (3.3)        | 21 (3.6)                             | 0.498   | 18 (4.0)                                 | 0.237   | 3 (2.3)                                                         | 0.237   |
| Cerebrovascular attack            | 12 (0.6)        | 2 (0.3)                              | 0.747   | 2 (0.4)                                  | 0.527   | 0                                                                 | 0.527   |
| Aspirin                           | 129 (6.3)       | 48 (8.3)                             | 0.037   | 34 (7.6)                                 | 0.410   | 14 (10.6)                                                       | 0.410   |
| Antithrombotics                   | 16 (0.8)        | 6 (1.0)                              | 0.436   | 6 (1.3)                                  | 0.344   | 0                                                                 | 0.344   |
| Nonsteroidal anti-inflammatory drug| 121 (5.9)      | 33 (5.7)                             | 0.887   | 26 (5.8)                                 | 0.666   | 7 (5.3)                                                         | 0.666   |
| Smoking                           | current         | 332 (16.3)                           | 86 (14.8)| 57 (12.7)                               | 0.075   | 29 (21.8)                                                       | 0.075   |
| past                              | 371 (18.2)      | 137 (23.6)                           | 105 (23.5)| 32 (44.1)                               | 0.546   | 77 (57.9)                                                       | 0.546   |
| never                             | 801 (39.3)      | 176 (30.3)                           | 139 (31.0)| 37 (27.8)                               | 0.594   | 77 (57.9)                                                       | 0.594   |
| No comment                        | 535 (26.2)      | 182 (31.3)                           | 147 (32.8)| 35 (26.3)                               | 0.594   | 77 (57.9)                                                       | 0.594   |
| Drinking                          | current         | 332 (16.3)                           | 86 (14.8)| 57 (12.7)                               | 0.075   | 29 (21.8)                                                       | 0.075   |
| past                              | 371 (18.2)      | 137 (23.6)                           | 105 (23.5)| 32 (24.1)                               | 0.546   | 77 (57.9)                                                       | 0.546   |
| never                             | 801 (39.3)      | 176 (30.3)                           | 139 (31.0)| 37 (27.8)                               | 0.594   | 77 (57.9)                                                       | 0.594   |
| No comment                        | 535 (26.2)      | 182 (31.3)                           | 147 (32.8)| 35 (26.3)                               | 0.594   | 77 (57.9)                                                       | 0.594   |
| Smoking                           | 0.546           |                                     | 0.594   |                                         |         |                                                                 |         |

Data are presented as the mean±SD or number (%).

Table 2. Test Findings of the Pseudo Group A Subjects with Past Infection

| Variable                          | True A (n=2,039) | Pseudo A with eradication history (n=448) | Pseudo A with endoscopic findings suggesting past infection (n=133) |
|-----------------------------------|-----------------|------------------------------------------|------------------------------------------------------------------|
| Pepsinogen I, ng/mL               | 51.8±21.1       | 54.2±25.4*                               | 51.3±23.5                                                       |
| Pepsinogen II, ng/mL              | 8.9±4.5         | 9.7±6.2*                                 | 9.3±5.0                                                        |
| Pepsinogen I/II ratio             | 6.4±4.5         | 6.2±3.7                                  | 5.7±1.5                                                        |
| Serology assay (Vidas)            | 1,160 (56.9)    | 208 (46.4)*                              | 73 (54.9)                                                      |
| Anti-H. pylori IgG titer          |                 |                                          |                                                                 |
| Vidas assay, AU/mL                | 0.42±0.20       | 0.50±0.21*                               | 0.44±0.23                                                      |
| Chorus assay, AU/mL               | 5.72±1.15       | 6.28±1.01*                               | 6.07±1.28                                                      |
| Serology titer in quartiles       |                 |                                          |                                                                 |
| First (lowest)                    | 578 (28.4)      | 70 (15.6)*                               | 36 (27.1)                                                      |
| Second                            | 662 (32.5)      | 111 (24.8)*                              | 38 (28.6)                                                      |
| Third                             | 449 (22.0)      | 129 (28.8)*                              | 27 (20.3)                                                      |
| Fourth (highest)                  | 350 (17.1)      | 138 (30.8)*                              | 32 (24.0)                                                      |

Data are presented as the mean±SD or number (%).

*Significantly different (p<0.05) from the true group A subjects; †Significant difference (p<0.05) between the two pseudo A groups.

H. pylori, Helicobacter pylori; IgG, immunoglobulin G.
group A subjects showed lower PG I and PG II levels (51.8±21.1 ng/mL and 8.9±4.5 ng/mL) than the pseudo group A subjects (53.6±25.0 ng/mL and 9.6±5.9 ng/mL). The serum anti-\textit{H. pylori} IgG titers were also lower in the true group A than their counterparts (Table 2).

4. Comparisons between the two pseudo group A subjects with past infection

The pseudo group A subjects with endoscopic findings suggesting past infection were older (p<0.001) and had a higher predominance of male sex (p<0.001) than the pseudo group A subjects with eradication history. The pseudo group A subjects with eradication history were born more recently (mean year of birth: 1957.6±9.8) than the pseudo group A subjects with abnormal endoscopic findings (1954.9±9.6). The quartiles of the anti-\textit{H. pylori} IgG titers also differed among the groups (Table 2).

5. Differences according to the quartiles of the serum anti-\textit{H. pylori} IgG titer

The subjects in the highest fourth quartile were older (p=0.001) and born earlier (p<0.001) than the subjects in the other quartiles (Table 3). Moreover, these subjects showed the highest mean PG II titer and the lowest PG I/II ratio among the subjects in all four groups. No difference was found among the groups with regard to smoking history (p=0.538), drinking history (p=0.634), recent intake of aspirin (p=0.378), antithrombotic drug intake (p=0.995), nonsteroidal anti-inflammatory drug

| Table 3. Differences Based on Quartiles of the Serum Anti-\textit{Helicobacter pylori} IgG Titer |
|-----------------------------------------------|
| Variable                                      | First quartile (n=684) | Second quartile (n=811) | Third quartile (n=605) | Fourth quartile (n=520) |
| Age, yr                                       | 50.4±11.8              | 50.1±11.6*              | 51.2±10.9*             | 52.5±10.2*               |
| Year of birth                                 | 1962.8±3.3             | 1961.9±11.6*            | 1961.0±11.2*           | 1959.4±10.5*             |
| Male sex                                      | 359 (52.5)             | 419 (51.7)*             | 324 (53.6)*            | 308 (59.2)*              |
| Pepsinogen I, ng/mL                           | 51.7±22.7              | 52.4±22.0               | 52.2±21.8              | 52.5±21.6                |
| Pepsinogen II, ng/mL                          | 8.6±4.8                | 9.1±4.7*                | 9.1±4.9*               | 9.5±4.9*                 |
| Pepsinogen I/II ratio                         | 6.6±3.2                | 6.2±2.9*                | 6.2±3.1*               | 5.9±2.3*                 |

Data are presented as the mean±SD or number (%).

Table 4. Comparisons between \textit{Helicobacter pylori}-Infected Subjects and Noninfected Subjects

| Variable                                      | H. pylori infection* (n=22) | No H. pylori infection (n=693) | p-value |
|-----------------------------------------------|-----------------------------|--------------------------------|---------|
| Age, yr                                       | 49.6±13.6                   | 51.9±11.4                     | 0.352   |
| Year of birth                                 | 1961.7±13.1                 | 1959.7±11.3                   | 0.429   |
| Male sex                                      | 15 (68.2)                   | 405 (58.4)                    | 0.361   |
| Pepsinogen I, ng/mL                           | 75.3±36.5                   | 52.0±22.3                     | <0.001  |
| Pepsinogen II, ng/mL                          | 16.4±7.9                    | 9.2±4.2                       | <0.001  |
| Pepsinogen I/II ratio                         | 5.4±1.7                     | 5.9±2.3                       | 0.327   |
| Serology assay (Vidas)                        | 16 (72.7)                   | 477 (68.8)                    | 0.697   |
| Serum anti-\textit{H. pylori} IgG titer, AU/mL| 0.54±0.25                   | 0.43±0.21                     | 0.052   |
| Vidas assay                                   | 5.95±0.95                   | 5.96±0.96                     | 0.984   |
| Quartiles of the serum anti-\textit{H. pylori} IgG | 4:3:7:8                     | 131:245:154:163               | 0.155   |
| True group A                                  | 16 (72.8)                   | 477 (68.9)                    | 0.854   |
| Pseudo group A with eradication history       | 3 (13.6)                    | 127 (18.3)                    |         |
| Pseudo group A with endoscopic findings       | 3 (13.6)                    | 89 (12.8)                     |         |

Data are presented as the mean±SD or number (%).

\*H. pylori infection was defined as positive test findings either in the urea breath test or on Giemsa staining on the day of endoscopy. Other variables (i.e., smoking, drinking, drug use, and comorbidities) are not shown owing to the lack of significant difference between groups.
use (p=0.136), presence of coronary heart disease (p=0.262), cerebrovascular disease (p=0.610), hypertension (p=0.480), and diabetes mellitus (p=0.329).

6. Group A subjects with current *H. pylori* infection

Among the 2,620 included subjects, 715 underwent the UBT or Giemsa staining on the same day of endoscopy (including 130 pseudo group A subjects with eradication history and 92 pseudo group A subjects with endoscopic findings suggesting past infection). Twenty subjects underwent both the UBT and Giemsa staining, and there was no discrepancy between the two tests in these subjects (all negative test findings). Other 599 subjects underwent Giemsa staining only, and 96 underwent UBT only. Positive test findings were found in 22 subjects (3.1%) (Supplementary Table 2). Among all variables, only the PG I and PG II levels differed between the *H. pylori* test-positive and -negative subjects (Table 4). The *H. pylori*-test findings were not affected by the anti-*H. pylori* IgG titer, age, year of birth, eradication history, and endoscopic findings suggesting past infection.

7. Independent risk factors for being pseudo group A owing to past infection

On multivariate analysis, age and year of birth were independent risk factors for being misclassified into group A despite past *H. pylori* infection (Table 5). The cutoff point for age was 50.5 years (sensitivity 72.1% and specificity 53.9%) on ROC curve analysis (p<0.001). The cutoff point for year of birth was 1959.5 (sensitivity 60.6% and specificity 61.2%, p<0.001) for being classified into pseudo group A (Fig. 2).

**DISCUSSION**

In this study, 22.2% of the group A subjects had past *H. pylori*...
Helicobacter pylori infection, and were found to be misclassified into group A. The subjects aged over 50 years and those born before 1960 were included in the high-risk groups for being misclassified into pseudo group A, either by previous eradication or spontaneous regression of H. pylori. Moreover, 3.1% of the subjects had current infection; however, being classified into pseudo group A owing to past infection did not increase the risk of current infection. Positive H. pylori test findings were correlated only with the PG I and PG II levels. Taken together, past infection should not be neglected in older subjects, and current infection should be ruled out in subjects with increased gastric secretory ability when using the ABC classification in a seroprevalent population.

Seroreversion usually occurs within a few years after H. pylori eradication or spontaneous regression. In addition to a rapid decrease in the anti-H. pylori IgG titer, the gastric secretory ability is often recovered after H. pylori regression. Therefore, many seroreversed subjects with past H. pylori infection can be misclassified into group A as shown in this study. In addition to those subjects who underwent intended H. pylori eradication, subjects after unintentioned eradication or those who showed spontaneous regression also revealed normal serum PG assay findings after seroreversion. Nonetheless, the gastric cancer risk remains high in the group A subjects with past infection. In our study, gastric neoplasm was found in three subjects in group A (0.1%), and two subjects showed endoscopic findings suggesting past infection. This is consistent with the findings of a recent study showing that most of the group A patients with gastric cancer had past H. pylori infection.

Older age was an independent risk factor for being classified into pseudo group A, with a cutoff point of 50.5 years in this study. Furthermore, group A Koreans born before 1960 had a higher risk. Mean year of birth was most remote (1955) in subjects with spontaneous regression, and was most recent (1963) in subjects without evidence of past infection. In subjects after successful eradication, mean year of birth (1958) was closer to that of subjects with spontaneous regression than subjects without evidence of past infection. Our findings are supported by the fact that more than 40% of group A subjects show atrophy on endoscopic findings, especially when they are older. Owing to these reasons, the ABC classification system is less useful for an older, seroprevalent population. Older subjects should be considered as having a high risk for gastric cancer owing to the high probability of past infection.

Another notable finding in this study is that 3.1% of the 715 group A subjects who underwent additional H. pylori test showed positive findings. Along with the seroreversed pseudo group A subjects with past infection, subjects with ongoing infection should not be neglected. False seronegative findings in infected Koreans may be due to non-availability of Korean serology assays at the clinic. The only Korean immunoassay, “Genesis H. pylori ELISA” from Green Cross Medical Science is available only for research purposes, and does not show quantitative results. Therefore, imported H. pylori IgG assays, which exhibited a similar diagnostic accuracy with the Genesis H. pylori ELISA in Koreans, were used in this study. Nonetheless, 22 infected subjects were misclassified into the seronegative group. Because these subjects showed high mean PG I (75.3 ng/mL) and PG II (16.4 ng/mL) levels, this could be improved by adding other H. pylori tests to the group A subjects with increased PG levels.

The pseudo group A subjects with eradication history showed a higher serum anti-H. pylori IgG titer than those with abnormal endoscopic findings suggesting past infection. Nonetheless, classification into pseudo group A and its correlated variables (i.e., old age, male sex, and earlier year of birth) did not increase the risk of current infection. The lack of a correlation between the increased serology titer and current infection supports the finding that the IgG titers decrease slowly after eradication. Despite such limitations, the ABC classification using the PG assay is still useful in Koreans with eradication history, because atrophy and metaplastic gastritis can be improved after eradication. Another Korean study showed that the PG I/II ratio of subjects becomes similar to that of normal controls after 5 years of eradication. The gastric biomarker levels in subjects with eradication history seem to recover to the level in noninfected subjects after 3 years, although a longer duration is needed in subjects with severe corpus atrophy.

There are limitations in our study. First, eradication history was based on the answers to questionnaires. There might have been a recall bias; however, the answers are usually reliable because it is not easy to forget 7 to 14 days of antibiotic intake for H. pylori eradication by intention. Moreover, in a seroprevalent population, the risk of providing imprecise information on past eradication might be lower than the risk of unintended eradication or spontaneous regression. Therefore, we hypothesized that the proportion of misclassified pseudo group A subjects owing to recall bias is small, and would not affect the main findings of this study. Second, additional H. pylori tests were performed only in 715 subjects. Nevertheless, we could verify that positive H. pylori test findings are correlated with the PG I and PG II levels, and not with the pseudo group A-related variables. This further suggests that current infection is uncommon even in pseudo group A subjects with a high serology titer.

In conclusion, 22.2% of the group A subjects were misclassified despite the gastric cancer risk, and the efficacy of the ABC classification method is limited owing to these pseudo group A seroreversed subjects. Along with pseudo group A subjects with past infection, those with current H. pylori infection can be misclassified into group A. Ongoing H. pylori infection should be considered in subjects with increased PG I and PG II levels, regardless of their age, serology titer, eradication history, and endoscopic findings. To discriminate seroreversed subjects with a risk of gastric cancer, past infection should be assessed in sub-
jcts aged over 50 years, especially in those born before 1960. Furthermore, current infection should be ruled out in subjects with increased gastric secretory ability.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGEMENTS

This work was supported by Konkuk University and National Research Foundation (2016R1D1A1B02008937).

AUTHOR CONTRIBUTIONS

Drafting of the manuscript: H.K., S.Y.L. Study concept and design: S.Y.L. Data acquisition, data analysis and interpretation, and statistical analysis: H.K., J.H.K., S.P.L. Administrative, technical support, and study supervision: J.H.K., I.K.S., H.S.P., C.S.S.

ORCID

Sun-Young Lee https://orcid.org/0000-0003-4146-6686

REFERENCES

1. Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer 2015;136:487-490.
2. Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 2017;153:420-429.
3. Peleteiro B, Bastos A, Ferro A, Lunet N. Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage. Dig Dis Sci 2014;59:1698-1709.
4. Carneiro F. Stomach cancer. In: Steward B, Wild CP, eds. World cancer report. Lyon: International Agency for Research on Cancer, 2014:383-391.
5. Shin A, Park S, Shin HR, et al. Population attributable fraction of infection-related cancers in Korea. Ann Oncol 2011;22:1435-1442.
6. Lee JH, Choi KD, Jung HY, et al. Seroprevalence of Helicobacter pylori in Korea: a multicenter, nationwide study conducted in 2015 and 2016. Helicobacter 2018;23:e12463.
7. Miki K, Fujishiro M, Kodashima S, Yahagi N. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc 2009;21:78-81.
8. Yamaguchi Y, Nagata Y, Hiratsuka R, et al. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels: the ABC Method. Digestion 2016;93:13-18.
9. Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels: "ABC method". Proc Jpn Acad Ser B Phys Biol Sci 2011;87:405-414.
10. Choi HS, Lee SY, Kim JH, et al. Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm. J Dig Dis 2014;15:293-298.
11. Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005;54:764-768.
12. Kiso M, Yoshihara M, Ito M, et al. Characteristics of gastric cancer in negative test of serum anti-Helicobacter pylori antibody and pepsinogen test: a multicenter study. Gastric Cancer 2017;20:764-771.
13. Kishikawa H, Kimura K, Ito A, et al. Cutoff pepsinogen level for predicting unintendedly eradicated cases of Helicobacter pylori infection in subjects with seemingly normal pepsinogen levels. Digestion 2017;95:229-236.
14. Chinda D, Shimoyama T, Mikami T, et al. Serum pepsinogen levels indicate the requirement of upper gastrointestinal endoscopy among group A subjects of ABC classification: a multicenter study. J Gastroenterol 2018;53:924-931
15. Boda T, Ito M, Yoshihara M, et al. Advanced method for evaluation of gastric cancer risk by serum markers: determination of true low-risk subjects for gastric neoplasm. Helicobacter 2014;19:1-8.
16. Maehata Y, Nakamura S, Esaki M, et al. Characteristics of primary and metachronous gastric cancers discovered after Helicobacter pylori eradication: a multicenter propensity score-matched study. Gut Liver 2017;11:628-634.
17. Lee SP, Lee SY, Kim JH, Sung IK, Park HS, Shim CS. Link between serum pepsinogen concentrations and upper gastrointestinal endoscopic findings. J Korean Med Sci 2017;32:796-802.
18. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969;1:87-97.
19. Sugimoto M, Ban H, Ichikawa H, et al. Efficacy of the Kyoto classification of gastritis in identifying patients at high risk for gastric cancer. Intern Med 2017;56:579-586.
20. Lee SY, Moon HW, Hur M, Yun YM. Validation of western Helicobacter pylori IgG antibody assays in Korean adults. J Med Microbiol 2015;64:513-518.
21. Kim JH, Lee SY, Lee SP, et al. The histologic detection of Helicobacter pylori in seropositive subjects is affected by pathology and secretory ability of the stomach. Helicobacter 2018;23:e12480.
22. Lee SY. Endoscopic gastritis, serum pepsinogen assay, and Helicobacter pylori infection. Korean J Intern Med 2016;31:835-844.
23. Koizumi W, Tanabe S, Imaizumi H, et al. Effect of anti-Helicobacter pylori IgG antibody titer following eradication of Helicobacter pylori infection. Hepatogastroenterology 2003;50:293-296.
24. Ohkusa T, Miwa H, Nomura T, et al. Improvement in serum pep-
sinogens and gastrin in long-term monitoring after eradication of Helicobacter pylori: comparison with H. pylori-negative patients. Aliment Pharmacol Ther 2004;20:25-32.

25. Miura K, Okada H, Kouno Y, et al. Actual status of involvement of Helicobacter pylori infection that developed gastric cancer from group A of ABC (D) Stratification - study of early gastric cancer cases that underwent endoscopic submucosal dissection. Digestion 2016;94:17-23.

26. Kotachi T, Ito M, Yoshihara M, et al. Serological evaluation of gastric cancer risk based on pepsinogen and Helicobacter pylori antibody: relationship to endoscopic findings. Digestion 2017;95:314-318.

27. Shimoyama T, Aoki M, Sasaki Y, Matsuzaka M, Nakaji S, Fukuda S. ABC screening for gastric cancer is not applicable in a Japanese population with high prevalence of atrophic gastritis. Gastric Cancer 2012;15:331-334.

28. Kang JM, Kim N, Shin CM, et al. Predictive factors for improvement of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication: a three-year follow-up study in Korea. Helicobacter 2012;17:86-95.

29. Nam SY, Jeon SW, Lee HS, Kwon YH, Park H, Choi JW. Long-term follow-up of pepsinogen I/II ratio after eradication of Helicobacter pylori in patients who underwent endoscopic mucosal resection for gastric cancer. Dig Liver Dis 2017;49:500-506.

30. Daugule I, Ruskale A, Moisejevs G, et al. Long-term dynamics of gastric biomarkers after eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2015;27:501-505.

31. Vannella L, Lahner E, Bordi C, et al. Reversal of atrophic body gastritis after H. pylori eradication at long-term follow-up. Dig Liver Dis 2011;43:295-299.